Elicio Therapeutics Inc. Company Profile
NASDAQ: ELTXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
Market open · Delayed 15 min · as of Oct 9, 10:11 AM ET
Elicio Therapeutics at a glance
Elicio Therapeutics Inc. (NASDAQ: ELTX) is a Biotechnology: Pharmaceutical Preparations company in the Health Care sector headquartered in Boston, MA. Elicio Therapeutics is led by Mr. Robert T. Connelly and employs about 33 people. The company's shares have traded publicly since 2021.
At a market capitalization of $47.6 million, it is considered a small-cap company. Its SEC Central Index Key (CIK) is 0001601485, which identifies the company's filings on EDGAR.
Summary generated from market data by MetaCap's automated system. Methodology
What does Elicio Therapeutics do?
Elicio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies for the treatment of cancer. Its lead product candidate, ELI-002, is a multivalent lymph node-targeted amphiphile (AMP) peptide vaccine that is in Phase II clinical trials for seven Kirsten rat sarcoma viral oncogene homolog driver mutations. The company also develops ELI-007, a multivalent lymph node-targeted AMP peptide treatment for mutant b-raf murine sarcoma viral oncogene homolog B1-(BRAF) driven cancers, and ELI-008, a multivalent lymph node-targeted AMP peptide vaccine in preclinical studies for the treatment of mutated tumor protein p53-expressing cancers. Elicio Therapeutics, Inc. is headquartered in Boston, Massachusetts.
Business description based on the company's public filings.
Company information
- Legal name
- Elicio Therapeutics Inc.
- Ticker
- NASDAQ: ELTX
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Robert T. Connelly
- Employees
- 33
- Headquarters
- 451 D Street, Boston, MA, United States
- Phone
- 857 209 0050
- Website
- elicio.com
- IPO year
- 2021
- Market cap
- $47.57M
- SEC CIK
- 0001601485
- Latest annual report
- 10-K/A · Apr 29, 2026
Companies similar to Elicio Therapeutics
| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| EDSAEdesa Biotech Inc. | 3.64 | -0.68% | $49.11M | vs ELTX |
| CPHIChina Pharma Holdings Inc. | 1.07 | +11.14% | $45.90M | vs ELTX |
| HOWLWerewolf Therapeutics Inc. | 0.94 | +3.30% | $45.69M | vs ELTX |
| CELUCelularity Inc. Class A | 1.53 | +4.79% | $49.65M | vs ELTX |
| DWTXDogwood Therapeutics Inc. | 1.47 | +3.82% | $49.80M | vs ELTX |
| CRVOCervoMed Inc. | 3.32 | +1.22% | $50.20M | vs ELTX |
| ANVSAnnovis Bio Inc. | 1.19 | +1.71% | $50.79M | vs ELTX |
| SERSerina Therapeutics Inc. | 2.00 | -0.50% | $50.80M | vs ELTX |